Maxim Group Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has initiated coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and a price target of $4.
September 11, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Context Therapeutics has been given a Buy rating by Maxim Group with a price target of $4.
The Buy rating and price target set by Maxim Group indicates a positive outlook for Context Therapeutics. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100